Sierra Summit Advisors’s Vir Biotechnology VIR Stock Holding History

Sierra Summit Advisors’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.5M	Buy	+134,420	New	+$1.34M	0.18%	85

Other funds holding VIR

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Raiffeisen Bank International Vienna, Austria $8.69B AUM 38.11% 1-Year Est. Return

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Virginia Retirement Systems Richmond, Virginia $16.3B AUM 35.33% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return

Yousif Capital Management Bloomfield Hills, Michigan $8.87B AUM 34.1% 1-Year Est. Return

Sierra Summit Advisors's VIR Position: Q3 2026 in Review

Sierra Summit Advisors opened a new position in Vir Biotechnology (VIR) in Q3 2026: 134,420 shares worth $1.5M. The stake represents 0.18% of the portfolio and ranks #85 among its holdings.

54 funds tracked by Wall St. Rank hold VIR as of Q3 2026.

Sierra Summit Advisors held 134,420 shares of Vir Biotechnology worth $1.5M as of Q3 2026.
Vir Biotechnology was a new Sierra Summit Advisors position in Q3 2026.
Vir Biotechnology made up 0.18% of Sierra Summit Advisors's portfolio in Q3 2026, its #85 holding.
54 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2026.

Based on Sierra Summit Advisors's 13F filing for Q3 2026, filed 28 Oct 2026.